Plus, news about Fennec, AstraZeneca, BiomX and Pfizer:
Bluebird bio gets more money: The gene therapy maker inked a five-year,
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
